New developments in anti-tumor efficacy and malignant transformation of human natural killer cells

Current Opinion in Hematology

Volumn 10, Issue 1, 2003, Pages 55-59

  VanDeusen, Jeffrey B ^a   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL KILLING; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; MALIGNANT TRANSFORMATION; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY, IMMUNOLOGIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL;

EID: 0037215551     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200301000-00009     Document Type: Review

References (39)

1. Caligiuri MA, Zmuidzinas A, Manley TJ, et al: Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990, 171:1509-1526.
2. Mier JW, Atkins MB. Interleukin 2. In Cancer: Principles and Practice of Oncology. Edited by Devita VT, Hellman S, Rosenberg SA. Lippincott Williams and Wilkins; 2001:471-476.
3. Caligiuri MA, Murray C, Soiffer RJ, et al: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immuno-modulation without significant toxicity. J Clin Oncol 1991, 9:2110-2119.
4. Soiffer RJ, Murray C, Cochran K, et al: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992, 79:517-526.
5. Soiffer RJ, Murray O, Gonin R, et al: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994, 84:964-971.
6. Karre K, Ljunggren HG, Piontek G, et al: Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986, 319:675-678.
7. Storkus WJ, Alexander J, Payne JA, et al: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A 1989, 86:2361-2364.
8. Shimizu Y, DeMars R: Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol 1989, 19:447-451.
9. Colonna M, Samaridis J: Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995, 268:405-408.
10. Routes JM: IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing. J Immunol 1992, 149:2372-2377.
11. Biassoni R, Cantoni C, Falco M, et al: The human leukocyte antigen (HLA)-C-specific 'activatory' or 'inhibitory' natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996, 183:645-650.
12. Moretta A, Biassoni R, Bottino C, et al: Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997, 155:105-117.
13. Lanier LL: NK cell receptors. Annu Rev Immunol 1998, 16:359-393.
14. Moretta L, Bottino C, Pende D, et al: Human natural killer cells: Their origin, receptors and function. Eur J Immunol 2002, 32:1205-1211.
15. Pende D, Cantoni C, Rivera P, et al: Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001, 31:1076-1086.
16. Costello RT, Sivori S, Marcenaro E, et al: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667. This study identifies a potential mechanism of immune escape by AML blasts that downregulate expression of NK cell activating ligands
17. Ruggeri L, Capanni M, Casucci M, et al: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
18. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100. A study that identifies a clear therapeutic benefit for mismatching donor NK cell inhibitory receptors against recipient HLA Class I ligands in allogeneic bone marrow transplants for the treatment of AML
19. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
20. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al: Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997, 89:3864-3872.
21. Drach J, Gattringer C, Huber H: Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 1991, 83:418-422.
22. Mann KP, DeCastro CM, Liu J, et al: Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997, 107:653-660.
23. Siu LL, Chan JK, Kwong YL: Natural killer cell malignancies: Clinicopathologic and molecular features. Histol Histopathol 2002, 17:539-554. A review of the common molecular and cytogenetic features in NK cell neoplasms
24. Ohshima K, Liu Q, Koga T, et al: Classification of cell lineage and anatomic site, and prognosis of extranodal T-cell lymphoma - Natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types. Virchows Arch 2002, 440:425-435. A thorough re-classification and prognostic analysis of 144 extranodal T-cell lymphomas into new classification schemas
25. Greer JP, Kinney MC, Loughran TP, Jr.: T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2001, 259-281. An excellent review of current knowledge on NK cell neoplasms
26. Jaffe ES: Nasal and nasal-type T/NK cell lymphoma: A unique form of lymphoma associated with the Epstein-Barr virus. Histopathology 1995, 27:581-583.
27. Liu Q, Ohshima K, Sumie A, et al: Nasal CD56 positive small round cell tumors. Differential diagnosis of hematological, neurogenic, and myogenic neoplasms. Virchows Arch 2001, 438:271-279.
28. Chan JK, Sin VC, Wong KF, et al: Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997, 89:4501-4513.
29. Imamura N, Kusunoki Y, Kawa-Ha K, et al: Aggressive natural killer cell leukaemia/lymphoma: Report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol 1990, 75:49-59.
30. Kuroda J, Kimura S, Akaogi T, et al: Aggressive natural killer cell leukemia/lymphoma: A comprehensive cytogenetic study by spectral karyotyping. Ann Hematol 2000, 79:519-522.
31. Lamy T, Loughran TP, Jr.: Current concepts: Large granular lymphocyte leukemia. Blood Rev 1999, 13:230-240.
32. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al: Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course. J Clin Oncol 2001, 19:2179-2188.
33. DiGiuseppe JA, Louie DC, Williams JE, et al: Blastic natural killer cell leukemia/lymphoma: A clinicopathologic study. Am J Surg Pathol 1997, 21:1223-1230.
34. Suzuki R, Nakamura S: Malignancies of natural killer (NK) cell precursor: Myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res 1999, 23:615-624.
35. Kimura S, Kakazu N, Kuroda J, et al: Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma. Ann Hematol 2001, 80:228-231.
36. Bayerl MG, Rakozy CK, Mohamed AN, et al: Blastic natural killer cell lymphoma/leukemia: A report of seven cases. Am J Clin Pathol 2002, 117:41-50.
37. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001, 107:351-362. This study identifies a potential role for the STAT family of proteins in the pathogenesis of large granular lymphocyte (LGL) leukemia
38. Fehniger TA, Suzuki K, Ponnappan A, et al: Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001, 193:219-231. This work identifies a role for interleukin (IL)-15 in the pathogenesis of NK cell leukemia and identifies an animal model for studying these disorders
39. Sood R, Stewart CC, Aplan PD, et al: Neutropenia associated with T-cell large granular lymphocyte leukemia: Long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998, 91:3372-3378.